Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: An assessment of currently available triazoles

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/ exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.

Original languageEnglish (US)
Pages (from-to)563-564
Number of pages2
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Coccidioidomycosis
Triazoles
Fluorides
Periostitis
Exostoses
Fluconazole
Therapeutics
posaconazole
Voriconazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

@article{65dd962ee6c543e5b9309a25b2839e83,
title = "Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: An assessment of currently available triazoles",
abstract = "The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/ exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.",
author = "Thompson, {George Richard} and Derek Bays and Cohen, {Stuart H} and Demosthenes Pappagianis",
year = "2012",
month = "1",
doi = "10.1128/AAC.05275-11",
language = "English (US)",
volume = "56",
pages = "563--564",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy

T2 - An assessment of currently available triazoles

AU - Thompson, George Richard

AU - Bays, Derek

AU - Cohen, Stuart H

AU - Pappagianis, Demosthenes

PY - 2012/1

Y1 - 2012/1

N2 - The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/ exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.

AB - The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/ exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.

UR - http://www.scopus.com/inward/record.url?scp=84455192484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455192484&partnerID=8YFLogxK

U2 - 10.1128/AAC.05275-11

DO - 10.1128/AAC.05275-11

M3 - Article

C2 - 22005993

AN - SCOPUS:84455192484

VL - 56

SP - 563

EP - 564

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -